HC Wainwright Has Positive Outlook of PepGen FY2027 Earnings

Key Points

• HC Wainwright raised its FY2027 EPS estimate for PepGen to a loss of $1.78 per share from $1.79 and maintained a “Buy” rating. The firm projects a $1.33-per-share loss for FY2029.
• Analyst sentiment is broadly positive: six analysts rate PepGen “Buy” and one rates it “Sell,” resulting in a “Moderate Buy” consensus rating and an average price target of $11.50.
• PepGen reported quarterly EPS of $(0.26), beating the $(0.28) consensus estimate. Its shares opened at $2.99, while hedge funds and other institutions own approximately 58% of the stock.

PepGen, Inc. (NASDAQ:PEPG - Free Report) - Equities research analysts at HC Wainwright raised their FY2027 earnings estimates for shares of PepGen in a research note issued on Friday, August 7th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of ($1.78) per share for the year, up from their previous estimate of ($1.79). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for PepGen's current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for PepGen's FY2029 earnings at ($1.33) EPS.

Other analysts have also recently issued research reports about the company. Craig Hallum assumed coverage on PepGen in a research report on Tuesday, June 16th. They set a "buy" rating and a $11.00 price target for the company. Wedbush reduced their price objective on PepGen from $5.00 to $4.00 and set an "outperform" rating for the company in a research note on Wednesday, May 13th. Wall Street Zen upgraded PepGen from a "sell" rating to a "hold" rating in a research note on Sunday, June 7th. Finally, Weiss Ratings downgraded PepGen from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, June 2nd. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $11.50.

PepGen Price Performance

NASDAQ PEPG opened at $2.99 on Tuesday. The company has a market cap of $207.09 million, a price-to-earnings ratio of -2.28 and a beta of 1.89. The stock's fifty day moving average price is $1.89 and its 200 day moving average price is $3.09. PepGen has a 1 year low of $1.01 and a 1 year high of $7.80.

PepGen (NASDAQ:PEPG - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02.

Hedge Funds Weigh In On PepGen

Institutional investors have recently made changes to their positions in the company. Rangeley Capital LLC boosted its holdings in PepGen by 133.3% during the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company's stock worth $39,000 after buying an additional 20,000 shares in the last quarter. Marshall Wace LLP purchased a new position in PepGen in the second quarter valued at $44,000. Burkehill Global Management LP purchased a new position in PepGen in the third quarter valued at $46,000. Militia Capital Partners LP acquired a new position in shares of PepGen in the third quarter worth about $72,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of PepGen by 94.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,202 shares of the company's stock worth $73,000 after acquiring an additional 5,453 shares during the period. 58.01% of the stock is owned by hedge funds and other institutional investors.

About PepGen

PepGen, Inc NASDAQ: PEPG is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source